Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Vepsitamab benchmark antibody ( Whole mAb, anti-MUC17;CD3E therapeutic antibody, Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-708
Product Details
Products Name (INN Index) | Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody |
---|---|
INN Name | Vepsitamab |
Target | MUC17,CD3E |
Format | Bispecific scFv-scFv-scFc |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | na;na |
VD LC | Lambda,Lambda |
Highest_Clin_Trial (Jan '20) | Phase-I |
Est. Status | Active |
100% SI Structure | None;None |
99% SI Structure | None;None |
95-98% SI Structure | None;None |
Year Proposed | 2021 |
Year Recommended | NA |
Companies | Amgen |
Conditions Approved | NA |
Conditions Active | GE Junction Cancer,Gastric Adenocarcinoma |
Conditions Discontinued | NA |
Development Tech | BiTE Technology |
Previous Name | NA |
Gm Offical Target Name | MUC17,CD3E |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide